Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kidney transplant drug halves the early risk of organ rejection

Research

Oxford University scientists have shown that a drug given at the time of a kidney transplant operation halves the risk of early rejection of the organ. The drug, called alemtuzumab, also allows a less toxic regimen of anti-rejection drugs to be used after the operation.

The researchers have reported their results in the medical journal The Lancet and have presented their findings at the World Transplant Congress in San Francisco.

Kidney transplantation is still the best treatment for patients with kidney failure, but much more subtle approaches are needed if success rates are to be improved.

Read more

Similar stories

Meta must do better - data from social media giant essential to mental health research

People are rightly sceptical about scientific discoveries made in secret or without scrutiny. And anyone claiming to have found a new planet with a toy telescope, would not be taken seriously. Recent leaks of internal Facebook research on the mental health of children and young people have caused a great stir on both sides of the Atlantic.

How moving dots are helping us learn more about dyslexia in children – new research

New research highlights importance of early years development on future wellbeing

Oxford researchers involved nearly 4,000 children across the UK in three specially developed science lessons to educate pupils about brain development during early childhood. The SEEN (Secondary Education around Early Neurodevelopment) project was commissioned and funded by KindredSquared and is part of a wider drive to increase public understanding of how early experiences can shape the adults we become.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.